Clinical Trials
11 trialsNCT05100134 2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available
NCT07215832 2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT05346835 2026-02-13
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
Janssen Scientific Affairs, LLC
Available
NCT03123029 2026-01-30
Expanded Access to Venetoclax
AbbVie
Available
NCT05161598 2025-12-16
Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)
Janssen Research & Development, LLC
No longer available
NCT05503550 2025-12-16
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
No longer available
NCT04771078 2025-12-12
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Celgene
Available
NCT05757973 2025-12-09
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing
NCT05164250 2025-11-10
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Approved for marketing
NCT05463939 2025-06-15
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
Janssen Research & Development, LLC
Approved for marketing
NCT04452994 2025-06-13
Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma
Janssen Research & Development, LLC
No longer available